Search

Displaying results 3891 - 3900 of 8517 in total
  1. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.

  2. Drug

    Sizofiran

    go.drugbank.com/drugs/DB13128
    Investigational

    It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.

  3. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  4. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.

  5. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with

  6. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tum...

  7. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    ._ and was granted FDA approval in 2007.[L6211]

  8. Drug

    Tanogitran

    go.drugbank.com/drugs/DB21367
    Investigational

    Tanogitran has a monoisotopic molecular weight of 477.25 Da. … Tanogitran is under investigation in clinical trial NCT02254057 (Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects).

  9. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo. … It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.

  10. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment